Lin Bioscience Stock

Lin Bioscience Liabilities

The The Liabilities of Lin Bioscience (6696.TWO) as of Jul 21, 2026 is 1.46 B TWD. In the previous year, The Liabilities was 617.92 M TWD — a change of 136.17% (higher).

Liabilities

1.46 BTWD

YoY

136.17%

Last updated:

In 2026, Lin Bioscience's total liabilities amounted to 1.46 B TWD, a 136.17% difference from the 617.92 M TWD total liabilities in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Lin Bioscience Stock analysis

What does Lin Bioscience do? Lin Bioscience is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Lin Bioscience's Liabilities

Lin Bioscience's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Lin Bioscience's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Lin Bioscience's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Lin Bioscience's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Lin Bioscience’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Lin Bioscience stock

The Liabilities of Lin Bioscience is 1.46 B TWD in 2026.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Lin Bioscience

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Lin Bioscience